$ALKS News

Major Decision: Nancy Snyderman Exercises Options, Realizing $116K At Alkermes

Alkermes plc 2026 Q2 - Results - Earnings Call Presentation

JP Morgan Maintains Neutral on Alkermes, Raises Price Target to $61

Baird Maintains Outperform on Alkermes, Raises Price Target to $58

Alkermes plc (ALKS) Q2 2026 Earnings Call Transcript

Alkermes (NASDAQ:ALKS) Reports Quality Earnings Beat but Stock Falls on Lack of Guidance

Piper Sandler Reiterates Overweight on Alkermes, Raises Price Target to $65

Conference Call: Alkermes Sees Q3 Sales $450.000M-$470.000M vs $472.751M Est

Alkermes Affirms FY2026 Sales Guidance of $1.730B-$1.840B vs $1.812B Est

Alkermes Q2 Sales $496.009M Beat $457.818M Estimate

Stifel Reiterates Buy on Alkermes, Raises Price Target to $63

Needham Maintains Buy on Alkermes, Raises Price Target to $62

Alkermes Says Lead Drug Maintains Wakefulness Benefits in Long-Term Narcolepsy Study

Alkermes Says Interim Analysis From Ogoing Long-term Extension Study Of Alixorexton For Narcolepsy Showed Sustained Clinically Meaningful Improvement In Wakefulness

JP Morgan Reinstates Neutral on Alkermes, Announces $60 Price Target

Mizuho Maintains Outperform on Alkermes, Raises Price Target to $65

BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns

Wells Fargo Maintains Overweight on Alkermes, Raises Price Target to $65

B of A Securities Downgrades Alkermes to Underperform, Announces $38 Price Target

Needham Maintains Buy on Alkermes, Raises Price Target to $61